


1. A chemical compound selected from the group consisting  
2 of an azole derivative having the formula:




3 and the pharmaceutically acceptable acid addition salts and stereo-  
4 chemically isomeric forms thereof, wherein:

5 Q is a member selected from the group consisting of CH and N;

6 Ar is a member selected from the group consisting of phenyl,  
7 thiienyl, halothienyl and substituted phenyl, said substituted phenyl  
8 having from 1 to 3 substituents each independently selected from the  
9 group consisting of halo, lower alkyl, lower alkyloxy and trifluoro-  
10 methyl; and

11 the radical Y is a member selected from the group consisting of

12 a 1H-pyrrol-1-yl radical of the formula




13 wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each independently selected  
14 from the group consisting of hydrogen, lower alkyl, aryl  
15 and aryl lower alkyl;

69

16

69

a 1H-pyrazol-1-yl radical of the formula




(b)

17 wherein R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are each independently selected from  
 18 the group consisting of hydrogen, lower alkyl, aryl and  
 19 aryl lower alkyl;

20

a 1H-imidazol-1-yl radical of the formula




(c)

21 wherein R<sup>8</sup> is selected from the group consisting of hydrogen,  
 22 lower alkyl, mercapto, lower alkylthio and aryl-lower  
 23 alkylthio, and R<sup>9</sup> and R<sup>10</sup> are each independently selected  
 24 from the group consisting of hydrogen, lower alkyl, aryl  
 25 and aryl lower alkyl;

26

a 1H-1,2,4-triazol-1-yl radical of the formula




(d)

27 wherein either of R<sup>11</sup> and R<sup>12</sup> is selected from the group con-  
 28 sisting of hydrogen, hydroxy, mercapto, lower alkylthio and  
 29 aryl-lower alkylthio, the remaining being selected from the  
 30 group consisting of hydrogen, lower alkyl and aryl-lower alkyl;

31

70


a 4H-1,2,4-triazol-4-yl radical of the formula



(e)

32 wherein  $\text{R}^{13}$  is selected from the group consisting of  
 33 hydrogen, mercapto, hydroxy, lower alkylthio and aryl  
 34 lower alkylthio, and  $\text{R}^{14}$  is selected from the group consist-  
 35 ing of hydrogen, lower alkyl, aryl and aryl lower alkyl;


36 a 2,3-dihydro-4H-1,2,4-triazol-4-yl radical of the formula



(f)

37 wherein  $\text{R}^{15}$  is selected from the group consisting of lower  
 38 alkyl and aryl lower alkyl and  $\text{R}^{16}$  is selected from the  
 39 group consisting of hydrogen, lower alkyl, and aryl lower  
 40 alkyl;

41 a 1H-1,2,3,4-tetrazol-1-yl radical of the formula



(g)

42 wherein  $\text{R}^{17}$  is selected from the group consisting of  
 43 hydrogen, mercapto, lower alkyl, aryl and aryl lower  
 44 alkyl;

45 wherein said aryl as used in the foregoing definition is selected  
 46 from the group consisting of phenyl and substituted phenyl,

47 said substituted phenyl having from 1 to 3 substituents each indepen-  
 48 dently selected from the group consisting of halo, lower alkyl, lower  
 49 alkyloxy and trifluoromethyl.

1 2. A chemical compound selected from the group consisting  
 2 of cis-1-{4-2-(2, 4-dichlorophenyl)-2-(1H-1, 2, 4-triazol-1-ylmethyl)-  
 3 1, 3-dioxolan-4-ylmethoxyphenyl}-4-4-(1H-imidazol-1-yl)phenyl-piperazine and the pharmaceutically acceptable acid addition salts  
 4 and stereochemically isomeric forms thereof.

1 3. A chemical compound selected from the group consisting  
 2 of cis-1-{4-2-(2, 4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-  
 3 1, 3-dioxolan-4-ylmethoxyphenyl}-4-4-(1H-1, 2, 4-triazol-1-yl)-  
 4 phenyl-piperazine and the pharmaceutically acceptable acid addition  
 5 salts and stereochemically isomeric forms thereof.

1 2 4. A chemical compound selected from the group consisting  
 2 of cis-4-{4-4-{4-2-(2, 4-dichlorophenyl)-2-(1H-imidazol-1-yl-  
 3 methyl)-1, 3-dioxolan-4-ylmethoxyphenyl}-1-piperazinylphenyl}-  
 4 2, 4-dihydro-2, 5-dimethyl-3H-1, 2, 4-triazol-3-one and the pharma-  
 5 ceutically acceptable acid addition salts and stereochemically isome-  
 6 ric forms thereof.

1 3 5. A chemical compound selected from the group consisting  
 2 of cis-4-{4-4-{4-2-(2, 4-dichlorophenyl)-2-(1H-1, 2, 4-triazol-1-  
 3 ylmethyl)-1, 3-dioxolan-4-ylmethoxyphenyl}-1-piperazinylphenyl}-  
 4 2, 4-dihydro-2, 5-dimethyl-3H-1, 2, 4-triazol-3-one monohydrate and  
 5 the pharmaceutically acceptable acid addition salts and stereo-  
 6 chemically isomeric forms thereof.

1 6. A chemical compound selected from the group consisting  
 2 of cis-1-{4-2-(2, 4-dichlorophenyl)-2-(1H-1, 2, 4-triazol-1-ylmethyl)-  
 3 1, 3-dioxolan-4-ylmethoxyphenyl}-4-4-(1H-imidazol-1-yl)phenyl-

4 piperazine and the pharmaceutically acceptable acid addition salts  
 5 and stereochemically isomeric forms thereof.

1 *NC*  
 2 *HP*  
 3  
 4  
 5  
 6 7. A chemical compound selected from the group consisting  
 of cis-1- $\{4-\overline{2}-(2,4\text{-dichlorophenyl})-2-(1\text{H-1,2,4-triazol-1-yl-}$   
 methyl)-1,3-dioxolan-4-ylmethoxyphenyl}-4- $\{4-\overline{3}-(methylthio)-$   
 1H-1,2,4-triazol-1-ylphenyl} piperazine and the pharmaceutically  
 acceptable acid addition salts and stereochemically isomeric  
 forms thereof.


1  
 2  
 3  
 4  
 5  
 6 8. A chemical compound selected from the group consisting  
 of cis-4- $\{4-\overline{4}-\{4-\overline{2}-(2,4\text{-dichlorophenyl})-2-(1\text{H-1,2,4-triazol-1-yl-}$   
 methyl)-1,3-dioxolan-4-ylmethoxyphenyl}-1-piperazinyl-phenyl}-2-ethyl-2,4-dihydro-5-methyl-3H-1,2,4-triazol-3-one  
 and the pharmaceutically acceptable acid addition salts and stereo-  
 chemically isomeric forms thereof.

1  
 2  
 3  
 4  
 5  
 6 9. A chemical compound selected from the group consisting  
 of cis-4- $\{4-\overline{4}-\{4-\overline{2}-(2,4\text{-dichlorophenyl})-2-(1\text{H-1,2,4-triazol-1-yl-}$   
 methyl)-1,3-dioxolan-4-ylmethoxyphenyl}-1-piperazinyl-phenyl}-2,4-dihydro-5-methyl-2-propyl-3H-1,2,4-triazol-3-one monohydrate and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

1  
 2  
 3  
 4  
 5  
 6 10. A chemical compound selected from the group consist-  
 ing of cis-4- $\{4-\overline{4}-\{4-\overline{2}-(2,4\text{-dichlorophenyl})-2-(1\text{H-1,2,4-triazol-1-yl-}$   
 methyl)-1,3-dioxolan-4-ylmethoxyphenyl}-1-piperazinyl-phenyl}-2-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one and  
 the pharmaceutically acceptable acid addition salts and stereo-  
 chemically isomeric forms thereof.

73

1           11. A composition for combatting the growth of a  
 2           microorganism selected from the group consisting of fungus  
 3           and bacterium comprising an inert carrier material and as an  
 4           active ingredient an effective antifungal or antibacterial amount  
 5           of a compound selected from the group consisting of an azole  
 6           derivative having the formula




7           and the pharmaceutically acceptable acid addition salts and  
 8           stereochemically isomeric forms thereof, wherein:

9           Q is a member selected from the group consisting of CH and N;

10          Ar is a member selected from the group consisting of phenyl,  
 11          thienyl, halothienyl and substituted phenyl, said substituted  
 12          phenyl having from 1 to 3 substituents each independently  
 13          selected from the group consisting of halo, lower alkyl, lower  
 14          alkyloxy and trifluoromethyl; and

15          the radical Y is a member selected from the group consisting of


15 a 1H-pyrrol-1-yl radical of the formula



(a)

16 wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each independently selected  
 17 from the group consisting of hydrogen, lower alkyl, aryl  
 18 and aryl lower alkyl;


19 a 1H-pyrazol-1-yl radical of the formula



(b)

20 wherein R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are each independently selected from  
 21 the group consisting of hydrogen, lower alkyl, aryl and  
 22 aryl lower alkyl;

23 a 1H-imidazol-1-yl radical of the formula




(c)

24 wherein R<sup>8</sup> is selected from the group consisting of hydro-  
 25 gen, mercapto, lower alkylthio and aryl lower alkylthio,  
 26 and R<sup>9</sup> and R<sup>10</sup> are each independently selected from the  
 27 group consisting of hydrogen, lower alkyl, aryl and  
 28 aryl lower alkyl;

29

a 1H-1, 2, 4-triazol-1-yl radical of the formula




(d)

30

wherein either of R<sup>11</sup> and R<sup>12</sup> is selected from the group consisting of hydrogen, hydroxy, mercapto, lower alkylthio and aryl-lower alkylthio, the remaining being selected from the group consisting of hydrogen, lower alkyl and aryl-lower alkyl;

35

a 4H-1, 2, 4-triazol-4-yl radical of the formula




(e)

36

wherein R<sup>13</sup> is selected from the group consisting of hydrogen, mercapto, hydroxy, lower alkylthio and aryl lower alkylthio, and R<sup>14</sup> is selected from the group consisting of hydrogen, lower alkyl, aryl and aryl lower alkyl;

40

a 2, 3-dihydro-4H-1, 2, 4-triazol-4-yl radical of the formula




(f)

41

wherein R<sup>15</sup> is selected from the group consisting of lower alkyl and aryl lower alkyl and R<sup>16</sup> is selected from the group consisting of hydrogen, lower alkyl, and aryl lower alkyl;


45 a 1H-1, 2, 3, 4-tetrazol-1-yl radical of the formula



46 wherein R<sup>17</sup> is selected from the group consisting of  
47 hydrogen, mercapto, lower alkyl, aryl and aryl lower  
48 alkyl;

49 wherein said aryl as used in the foregoing definition is selected  
50 from the group consisting of phenyl and substituted phenyl, said  
51 substituted phenyl having from 1 to 3 substituents each independently  
52 selected from the group consisting of halo, lower alkyl, lower  
53 alkyloxy and trifluoromethyl.

1 12. A chemical compound having the formula




2 and the pharmaceutically acceptable acid addition salts and  
3 stereochemically isomeric forms thereof, wherein:

4 Q is a member selected from the group consisting of CH and N;

5 Ar is a member selected from the group consisting of phenyl,  
6 thiienyl, halothienyl and substituted phenyl, said substituted  
7 phenyl having from 1 to 3 substituents each independently  
8 selected from the group consisting of halo, lower alkyl,  
9 lower alkyloxy and trifluoromethyl.

1        13. A composition for combatting the growth of a micro-  
 2        organism selected from the group consisting of fungus and bacterium  
 3        comprising an inert carrier material and as an active ingredient an  
 4        effective antifungal or antibacterial amount of a compound selected from  
 5        the group consisting of an azole derivative having the formula



6        and the pharmaceutically acceptable acid addition salts and stereo-  
 7        chemically isomeric forms thereof, wherein:

8        Q is a member selected from the group consisting of CH and N;

9        Ar is a member selected from the group consisting of phenyl,  
 10      thiienyl, halothienyl and substituted phenyl, said substituted  
 11      phenyl having from 1 to 3 substituents each independently  
 12      selected from the group consisting of halo, lower alkyl,  
 13      lower alkyloxy and trifluoromethyl.

1        14. A chemical compound selected from the group consisting  
 2        of cis-1- $\{$  4- $\underline{2}$ -(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-  
 3        1,3-dioxolan-4-ylmethoxy $\}$  phenyl  $\}-4$ - $\underline{4}$ -(1H-tetrazol-1-yl)phenyl $\}-$   
 4        piperazine and the pharmaceutically acceptable acid addition salts  
 5        and stereochemically isomeric forms thereof.

*add  
a'*